About OptimizeRx

Steve Silvestro brings more than 20 years’ experience in direct operations, sales, and partner network growth, to lead revenue activities and strengthen the go-to-market.

Steve is responsible for driving OptimizeRx's platform revenue growth including enterprise-level direct-to-patient and direct-to-provider product adoption to improve patient outcomes.
‍
During his tenure at Decision Resources Group, he was an instrumental leader in the growth of the company from $30 million to $180 million in revenue. His customer-first philosophy is greatly aligned to our values at OptimizeRx.
‍
Steve previously served as vice president and general manager at CCH Tagetik, a division of Wolters Kluwer. Prior pharma leadership experience includes executive positions with Prognos, Decision Resources Group and D.M.S. Silvestro has extensive channel expertise in biopharma commercialization, global market access, market research, analytics, enterprise SaaS solutions and strategy.
‍
Silvestro received a master’s degree in Business Management from Harvard University. He also holds undergraduate degrees from Brigham Young University in both Business and Italian. He is fluent in English, Italian, Spanish and conversational in French.

Ed has over 30 years of diverse experience at organizations going through transformational changes, including international expansions, new product launches, financial/operational turnarounds, mergers & acquisitions, resource prioritization, strategy creation, and digital innovation. In his senior leadership roles, Ed has continually brought lasting positive culture changes and purpose to the organizations he serves.

Prior to joining OptimizeRx Ed served in a variety of leadership roles at Otsuka America Pharmaceuticals Inc. His tenure with Otsuka began as a CFO leading the finance team on a transformative journey to help steer the organization through Abilify loss of exclusivity (LOE). It culminated in an appointment as CFO/COO to lead a ~400 person, multi-functional team of professionals through product lifecycle management, new product launches, strategy development, alliance governance, M&A and COVID-19 response. Over his tenure, the US organization evolved to be one of the best performing businesses for Otsuka globally and built best-in-class capabilities across a number of key enterprise functions through significant process optimization and automation initiatives.

Ed’s career has taken him across the globe, including foreign expat assignments in the Netherlands and Russia. He has held positions of increasing responsibilities in finance and operations at Covance/LabCorp, Mylan, Organon/Schering-Plough, Sanofi-Aventis and Johnson & Johnson.

Outside of work, Ed serves as the Treasurer and Executive Committee member of the American Foundation of Suicide Prevention in NYC, and as a member of the Advisory Committee of the Arts Council of Princeton.

He received his Bachelor of Science in Finance from Towson University and his MBA from the University of Baltimore. He is also a Certified Public Accountant (inactive) in the State of New Jersey and a Certified Management Accountant. He is married with two adult children, and fluent in Russian.

Marion is a corporate lawyer with over 25 years of large firm and in-house experiences in a broad range of industries including life sciences, biotech, high tech, business consulting, professional services, banking and finance companies. She is a critical thinker with strong global management, leadership, analytical, communication and problem-solving skills with emphasis on providing practical and proactive solutions to complex legal and business issues in both the domestic and international arenas.

Marion oversees the Compliance/Corporate Governance, and Legal/Contracts teams. Her areas of expertise include corporate, mergers and acquisitions and securities; complex transactions and global commercial contracts; privacy and IT security compliance; technology and licensing; labor and employment; corporate policy development and training; and corporate governance and board relations.

Prior to joining OptimizeRx, Marion worked in various leadership roles in both public and private companies. She began her legal career in private practice at the Boston law firm of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC, where she advised public and private companies on corporate matters.

Marion received her J.D. from Northeastern University, her M.Phil from the University of Cambridge, and her B.A. from Columbia University. Marion lives in Cambridge, Massachusetts, is married, has two adult children, and is fluent in Korean and proficient in Italian.

A seasoned financial leader with a strong background in healthcare and capital markets, Andy D'Silva brings nearly 15 years of experience driving growth and strategic transformation. His expertise spans corporate finance, business development, investor relations, and M&A, with a proven track record of helping organizations optimize capital allocation and create long-term shareholder value.
‍
Andy joined the Company in 2021 and has played a critical role in shaping its financial strategy and growth trajectory. Prior to his current role as Chief Business Officer, he served as Senior Vice President of Corporate Finance, where he oversaw FP&A, investor relations, and supported the Company’s M&A activities in collaboration with senior leadership.
‍
Earlier in his career, Andy was a Senior Healthcare Research Analyst at B. Riley Securities and a Managing Director on Merriman Capital’s equity research team, where he developed deep expertise in healthcare equity markets. He began his career in the construction industry as a Project Manager, working closely with real estate development companies.
‍
Andy holds a bachelor’s degree in Economics from the University of California, San Diego.

Brendan brings 15+ years of healthcare operations, customer success and sales leadership experience. Delivering results for colleagues, customers and organizations served.  
‍
Joining OptimizeRx in 2020, Brendan performed roles of increasing responsibility in operational and commercial leadership. Prior to his current role serving as Senior Vice President of Client Strategy and Program Management. In this capacity he led the transformation of multiple functions to drive organizational focus and measurable advancement in operational excellence and operating leverage.  
‍
Brendan spent the 9+ years prior in life sciences strategic decision-support. Leading teams partnering with top pharmaceutical manufacturers provisioning data informing portfolio and brand investment strategies, culminating in his role at DRG as Senior Vice President and Head of Commercial Excellence. Throughout each phase of his career in leadership, Brendan has brought together and enabled engaged, high performing teams, direct and cross-functional.  
‍
Brendan holds a Bachelor of Arts degree from Union College in Schenectady, NY.

Sarah Bast is Chief Marketing Officer of OptimizeRx, where she leads the company's marketing strategy, brand positioning, and go-to-market initiatives. A recognized healthcare marketing leader with more than 20 years of experience, Sarah has built and led high-performing teams across pharmaceutical media, omnichannel strategy, point-of-care, electronic health records (EHR), and digital innovation. 

Prior to joining OptimizeRx in 2026, she served in senior leadership roles at Publicis Health Media, where she developed the agency's specialized Point of Care and EHR practice and led marketing and media strategy for many of the industry's leading pharmaceutical companies, including Eli Lilly, Bayer, Johnson & Johnson, and AstraZeneca. Sarah also served on the Board of Directors of the Point of Care Marketing Association (POCMA).

Sarah holds a bachelor's degree from Penn State.

As Chief AI Officer at OptimizeRx, Mike advances the frontier of HCP & DTC healthcare marketing through innovative uses of data and technology. Drawing on nearly 15 years of experience applying Artificial Intelligence to drive business value, including prior roles at Athenahealth, Clarivate and HubSpot, he creates tailored solutions to increase the clinical relevance of life science brand communications, optimize the feedback loop between life sciences and providers, and support better patient outcomes.
‍

Mike holds Bachelors Degrees in Economics and Finance from Rochester Institute of Technology in Rochester, NY.

Lynn is the President and CEO of the Muscular Dystrophy Association (MDA), the leader in the fight against muscular dystrophy and ALS through its funding of research, clinical care, support service, and education.

Lynn has a hands-on appreciation for patient care, and she has considerable executive experience and expertise in the fields of pharmacology, medical and clinical education, and digital marketing.

Prior to her arrival at MDA, Lynn was CEO of ghg | greyhealth group for nearly 23 years and is credited with creating, building and acquiring companies — specifically, nine acquisitions — to grow ghg’s global footprint. While at ghg, Vos led global expansion and diversification strategies and within two years grew the company from a small, domestic professional player into an award-winning global enterprise with fully integrated, multi-channel offerings.

She is a recognized thought leader in the industry with published white papers and articles outlining new, successful approaches to health care technology and communication.

Cathy Klema has over 30 years of experience in the healthcare industry. Prior to establishing Nettleton Advisors, she served as Managing Director in the Healthcare Investment Banking groups at SG Cowen Securities and Furman Selz LLC, where she advised clients on mergers and acquisitions, divestitures, public offerings, and other strategic transactions. Ms. Klema is currently Chair of the Board of Managers of Quorum Health, a leading health system with 12 hospitals across 10 states. She also serves on the Board of Trustees of Montefiore Health System, a prominent academic health system in New York City. Previously, she was a Director of Allergan plc, a global pharmaceutical company, and Pharmaceutical Product Development, Inc., a global contract research organization.

Mr. Lang brings to OptimizeRx more than 25 years of experience in healthcare data, analytic, and technology enabled business services.

Lang presently serves as an executive advisor to Water Street, a strategic private equity firm focused exclusively on building market-leading companies in healthcare. He is also a director of BioVie, a development-stage company pioneering an innovative therapeutic that targets complications due to liver cirrhosis.

Previously, Mr. Lang served as CEO of Decision Resources Group, DRG, a leading healthcare research and consulting company providing high-value healthcare industry analysis and insights, where he helped transform the company into an industry leader. Earlier, he was president of Strategic Decisions Group, a premier global strategy consultancy, and he expanded the life sciences practice and later sold it to IMS Health.

He is an active private investor and advisor with healthcare companies, including Boston Heart Diagnostics (acquired by Eurofins) and AlphalmpactRx (acquired by IMS Health).

James Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire, and earned an MBA with distinction from the Tuck School of Business where he was named an Edward Tuck Scholar.He currently guest lectures at the Tuck School of Business in strategy and decision-making.

Patrick Spangler has over 32 years of experience in IPO’s, mergers and acquisitions, operations and financial management experience in the medical device and health care IT industries. As a transformational leader he has been responsible for driving high-performance emerging growth firms as well as large publicly traded companies and has also served in the private equity sector successfully improving operational results and exit strategies with a broad array of portfolio companies. He currently serves as Chief Financial Officer of On Target Laboratories which has developed fluorescent markers to target and illuminate cancer during surgery. Prior to On Target Laboratories, Pat served as Chief Financial Officer of MHC Software supplying document automation software to a variety of industries. Previous to MHC, Pat served as Chief Financial Officer of Vigilanz Corporation, Chief Financial Officer of Healthland Inc, SVP and CFO for Epocrates (EPOC), SVP and CFO of ev3 Inc. (EVVV), and Executive Vice President and Chief Financial Officer and Assistant Secretary for EMPI Inc (EMPI). Prior to joining EMPI Inc. Pat served for over eleven years in various senior finance leadership positions at Medtronic, Inc (MDT).

Pat holds a Bachelor of Science in Accounting from the University of Minnesota, a Master of Business Taxation from the University of Minnesota and a Master of Business Administration from University of Chicago and also serves on the Board of Directors of Lifespace Communities Inc, OptimizeRx (OPRX) and previously served on the board of Urologix Inc (ULGX) a leader in less invasive in office BPH treatment.

Greg Wasson founded Wasson Enterprise, a family office that partners to build sustainable, high-growth businesses that do well by doing good. Wasson Enterprise brings a wealth of knowledge, including leadership, operations and governance experience to those WE supports. Additionally, Greg is a Co-Founder of CoolerScreens, Co-Founder and Director of Golden Fleece Beverages Inc., Co-Founder of Innventure, and Executive Chairman of Innovation Associates.

As the former President and CEO of Walgreens, Greg led this Fortune 35 company to record fiscal 2014 sales of $76.4 billion. He is credited with creating significant financial and shareholder value, initiating and completing game-changing mergers and acquisitions, leading complex organizational and structural change, assembling a diverse and high-performance senior leadership team, and establishing Walgreens’ position as an industry leader. Before retiring from Walgreens, Greg had transformed an iconic 114-year-old domestic company into the first global pharmacy-led, health, well-being, and beauty enterprise via the successful merger with European-based Alliance Boots to create Walgreens Boots Alliance.

Greg began his career as a pharmacy services intern in the Walgreens corporate offices—an opportunity that led to his being hired by Walgreens upon graduation. Greg then spent many years in store operations, leading and opening new markets around the country. Greg also had the opportunity to run Walgreens Health Services which gave him a keen insight to the health care services side of the Walgreens business. This role eventually led to Greg becoming the COO of Walgreens. Greg was with Walgreens for 35 years, retiring as the President and CEO of Walgreens Boots Alliance. He received his BS in pharmacy in 1981 from Purdue University and is a registered pharmacist.

Greg serves on the boards of Health Care Service Corporation (HCSC), Cooler Screens, Performance Health Systems, Innovation Associates, Innventure, OptimizeRx, The Economic Club of Chicago, Corporate Leadership Center, and AUSL.

Mary Varghese Presti is a healthcare and technology executive who has spent her career helping organizations navigate periods of significant change. Today, she serves as Corporate Vice President and COO for Microsoft's Health & Life Sciences business, leading transformation efforts across product, engineering, operations, commercialization, and AI adoption.

A pediatric nurse by training, Mary began her career at Johns Hopkins Hospital before helping shape national health IT and payment reform initiatives at Booz Allen Hamilton. Since then, she has held leadership roles across healthcare, life sciences, and technology, including Pfizer, athenahealth, IBM Watson Health, Nuance, and Microsoft.

Throughout her career, she has been drawn to moments when technology fundamentally changes how healthcare is delivered. At Microsoft and Nuance, she helped incubate and scale AI-powered clinical workflow innovations, including early work that evolved into what is now Dragon Copilot for Nursing. She also led the Dragon Medical business during a period of international expansion and rapid adoption of ambient and generative AI technologies.

Today, her focus is on a broader transformation: helping healthcare organizations, workforces, and business models adapt to the age of AI. She believes the greatest opportunity is not simply deploying new technology, but helping people and institutions reimagine how care is delivered, how work gets done, and how innovation creates meaningful outcomes for patients, clinicians, and healthcare systems.